Atezolizumab

A randomized phase 3 trial designed to evaluate tiragolumab plus atezolizumab for certain patients with advanced lung cancer failed to meet its co-primary endpoint of OS, according to the agents’ manufacturer

Concurrent administration of chemoradiation and immunotherapy did not improve survival for patients with limited-stage small cell lung cancer, according to a study presented at American Society for Radiation Oncology Annual Meeting.

The addition of lurbinectedin to atezolizumab improved survival for certain adults with lung cancer, according to the agent’s manufacturer.

In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab ‘may be a new standard’ and more.

The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.

Neoadjuvant atezolizumab prior to chemoradiation therapy exhibited promising activity for patients with unresectable stage III non-small cell lung cancer, according to results of a nonrandomized phase 2 study.

A randomized phase 3 trial designed to compare two combinations for first-line treatment of lung cancer has been halted after an interim analysis revealed no survival benefit and more toxicity with the experimental regimen.

In this edition, atezolizumab benefits PD-L1-selected patients with NSCLC, risks persist with e-cigarette use after quitting tobacco smoking and more.

CHICAGO — Updated survival data from the randomized phase 3 IMpower010 continued to support adjuvant atezolizumab for patients with stage II to stage IIIA PD-L1-expressing non-small cell lung cancer, according to researchers.

Tiragolumab plus atezolizumab added to chemotherapy did not extend survival outcomes as first-line therapy of locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, interim results from a randomized study showed.